SDC1 and plasma cell myeloma: The dying myeloma cells (U266 cell lines and CD138+ cells from patients) treated with 400 nM chaetocin and 100 nM Bortezomib (Sigma-Aldrich) showed higher expression of HSP90 than untreated myeloma cells or UVB-irradiated myeloma cells (Figure 1C) or isotype control (Supplementary Figure 1).